Stock Market Reviews

XENE (Xenon Pharmaceuticals Inc.) News

Get the latest news, insights, and market updates on XENE (Xenon Pharmaceuticals Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  VANCOUVER, British Columbia and BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to five new non-officer employees consisting of an aggregate of 39,250 share options. All of the foregoing share options were approved by the Compensation Committee of
  Dec 4, 2025 - $XENE
• Mirum Pharmaceuticals (MIRM) Up 1.3% Since Last Earnings Report: Can It Continue?
  Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
  Dec 4, 2025 - $XENE
• Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025
  VANCOUVER, British Columbia and BOSTON, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will host an investor webinar focused on its data presentations at the American Epilepsy Society Annual Meeting (AES 2025), including new long-term data from the ongoing X-TOLE
  Dec 3, 2025 - $XENE
• Why Is Xenon Pharmaceuticals (XENE) Up 9.7% Since Last Earnings Report?
  Xenon Pharmaceuticals (XENE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
  Dec 3, 2025 - $XENE
• Xenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025
  Seven posters to be presented, including new X-TOLE OLE data supporting the ability to attain and regain extended periods of seizure freedom with long-term use of azetukalnerData will also highlight the impact of depression and burden of titration on patients with epilepsy, as well as new pre-clinical data from the Company’s NaV1.1 program in Dravet syndrome VANCOUVER, British Columbia and BOSTON, MA, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-foc
  Nov 25, 2025 - $XENE
• Xenon to Present at Upcoming Investor Conferences
  VANCOUVER, British Columbia and BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the Company will present at two upcoming investor conferences. Stifel 2025 Healthcare ConferenceThursday, November 13, 2025 at 3:20 PM ET Webcast link here Jefferies Global Healthcare Confe
  Nov 6, 2025 - $XENE
• Xenon Pharmaceuticals (XENE): Losses Widen 37% Annually, Challenging Bullish Revenue Growth Expectations
  Xenon Pharmaceuticals (XENE) posted another year of heavy losses, with net profit margins remaining deeply negative and losses rising at an average annual rate of 37% over the last five years. Even as profitability continues to be elusive, revenue is forecast to surge by 72.4% per year, well ahead of the US market’s projected 10.5% annual growth. Robust revenue growth prospects and a share price trading below some analyst targets give investors reason for optimism, even as persistent...
  Nov 5, 2025 - $XENE
• Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus
  XENE reports narrower-than-expected Q3 loss as the biotech advances multiple late-stage studies of azetukalner across epilepsy and mood disorders.
  Nov 4, 2025 - $XENE
• Xenon Pharmaceuticals Inc (XENE) Q3 2025 Earnings Call Highlights: Strong Financial Position ...
  Xenon Pharmaceuticals Inc (XENE) exceeds patient enrollment goals in its Phase 3 XTOL2 study and maintains a robust cash runway into 2027, despite facing market competition and upcoming expenses.
  Nov 4, 2025 - $XENE
• Xenon Reports Third Quarter 2025 Financial Results & Business Update
  – Phase 3 X-TOLE2 FOS topline data on track to read out early 2026 with patient randomization complete – Phase 3 X-NOVA2 and X-NOVA3 studies in MDD & Phase 3 X-CEED study in BPD continuing to recruit – Phase 1 Nav1.7 & Kv7 studies underway – Tucker Kelly appointed as Chief Financial Officer, bringing extensive strategic commercial finance experience in anticipation of the azetukalner launch – Conference call at 4:30 pm ET today VANCOUVER, British Columbia and BOSTON, Nov. 03, 2025 (GLOBE NEWSWIR
  Nov 3, 2025 - $XENE